Recently completed and ongoing studies targeting adhesion
| Study title . | Clinical trials #/Phase . | Intervention . | Status . | Primary sponsor . |
|---|---|---|---|---|
| Selectin inhibitors | ||||
| Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis | NCT01119833 Phase 2 | GMI-1070 (rivipansel) | Complete | GlycoMimetics |
| Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease | NCT02187003 Phase 3 | GMI-1070 (rivipansel) | Ongoing | Pfizer |
| Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises | NCT01895361 Phase 2 | SelG1 | Ongoing | Selexys |
| Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD | NCT02515838 Phase 2 | Sevuparin | Ongoing | Dilaforette |
| β blockers | ||||
| Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD) | NCT01077921 Phase 2 | Propranolol | Complete | Duke Univ. |
| Propranolol and Red Cell Adhesion in Non-asthmatic Children with Sickle Cell Disease | NCT02012777 Phase 1 | Propranolol | Ongoing | Univ. of Miami |
| Other inhibitors of adhesion | ||||
| Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease | NCT00004408 Phase 3 | Poloxamer 188 | Complete | Mast Therapeutics. CytRx |
| Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) | NCT01737814 Phase 3 | Poloxamer 188 | Ongoing | Mast Therapeutics |
| Study title . | Clinical trials #/Phase . | Intervention . | Status . | Primary sponsor . |
|---|---|---|---|---|
| Selectin inhibitors | ||||
| Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis | NCT01119833 Phase 2 | GMI-1070 (rivipansel) | Complete | GlycoMimetics |
| Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease | NCT02187003 Phase 3 | GMI-1070 (rivipansel) | Ongoing | Pfizer |
| Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises | NCT01895361 Phase 2 | SelG1 | Ongoing | Selexys |
| Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD | NCT02515838 Phase 2 | Sevuparin | Ongoing | Dilaforette |
| β blockers | ||||
| Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD) | NCT01077921 Phase 2 | Propranolol | Complete | Duke Univ. |
| Propranolol and Red Cell Adhesion in Non-asthmatic Children with Sickle Cell Disease | NCT02012777 Phase 1 | Propranolol | Ongoing | Univ. of Miami |
| Other inhibitors of adhesion | ||||
| Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease | NCT00004408 Phase 3 | Poloxamer 188 | Complete | Mast Therapeutics. CytRx |
| Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) | NCT01737814 Phase 3 | Poloxamer 188 | Ongoing | Mast Therapeutics |